Pancreatic ATP-sensitive potassium channel (K_ATP channel)

The pancreatic ATP-sensitive potassium (K_ATP) channel is a hetero-octameric protein complex located in the plasma membrane of pancreatic beta cells, composed of four inward-rectifier potassium channel 6.2 (Kir6.2) subunits and four sulfonylurea receptor 1 (SUR1) subunits (Nichols, C. G., 2006, Nature). It serves as a critical metabolic sensor that couples the intracellular ATP/ADP ratio to the cell's membrane potential, thereby regulating insulin secretion in response to blood glucose levels (Ashcroft, F. M., 2005, Nature). When blood glucose rises, increased oxidative metabolism elevates the ATP/ADP ratio, causing the K_ATP channel to close, which triggers membrane depolarization, calcium influx, and the exocytosis of insulin granules (Aguilar-Bryan, L., & Bryan, J., 1999, Endocrine Reviews). Dysregulation of this channel is central to several metabolic disorders; gain-of-function mutations in the encoding genes (KCNJ11 and ABCC8) lead to neonatal diabetes, while loss-of-function mutations cause congenital hyperinsulinism (StatPearls: Physiology, Adenosine Triphosphate Sensitive Potassium Channels). Pharmacologically, the channel is the primary target for sulfonylureas and meglitinides, which promote insulin release in type 2 diabetes by inducing channel closure (Proks, P., et al., 2002, Diabetes). Conversely, channel openers like diazoxide are used to treat hyperinsulinemic states by preventing depolarization and suppressing insulin secretion (Gribble, F. M., & Reimann, F., 2003, Diabetologia). This dual role makes the K_ATP channel a cornerstone of glucose-stimulated insulin secretion and a vital therapeutic target in metabolic medicine.

Other names

KATP channelKir6.2/SUR1 complexATP-sensitive inward rectifier potassium channelSulfonylurea receptor 1-inward rectifier potassium channel 6.2 complexBeta-cell ATP-sensitive potassium channelKCNJ11/ABCC8 complex

Drugs targeting the pancreatic K_ATP channel primarily act by modulating its open-state probability; sulfonylureas and meglitinides bind to the SUR1 subunit to induce channel closure, membrane depolarization, and insulin secretion, whereas potassium channel openers like diazoxide bind to SUR1 to stabilize the open state, thereby inhibiting insulin release.